2-AG Modulation for Migraine Relief With Lower Side-Effect Burden

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for headaches, particularly migraines, are limited in effectiveness and suffer from moderate tolerability and serious side effects, highlighting the need for improved methods to prevent or treat headache-related pain.

Innovation Solution

Enhancing 2-arachidonoyl glycerol (2AG) tone and reducing prostaglandin activity in a subject by administering pharmaceutical compositions that inhibit MAGL, ABHD6, or ABHD12 enzymes, or enhance DAGL activity, thereby modulating the endocannabinoid system to alleviate headache symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional pharmacologic interventions (ergot alkaloids, opiates, 3-adrenergic antagonists, NSAIDs, topiramate, serotonin agonists) are used to treat migraine, then headache symptoms can be reduced in some patients, but the treatments exhibit diverse nature with variable responses, limited tolerability, and serious long-term side effects

Engineering Contradiction:

Improveeffectiveness of headache treatmentVSAvoidside effects and tolerability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the biochemical parameter by targeting the endocannabinoid system specifically, using MAGL inhibitors to increase 2-AG levels. This shifts from non-selective pharmacologic interventions to a targeted molecular mechanism, improving reliability while reducing harmful side effects associated with conventional diverse drug classes

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces 2-arachidonoyl glycerol (2-AG) as a key intermediary substance in the endocannabinoid system. By enhancing 2-AG tone through MAGL inhibition, the patent creates a new therapeutic intermediary that mediates pain relief through cannabinoid receptor activation, avoiding the need for conventional diverse pharmacologic agents

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If non-selective drugs with multiple receptor activities are used to treat migraine, then headache can be treated, but the diverse nature of the disorder results in variability in patient responses

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidpatient response variability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the approach from non-selective multi-receptor drugs to a selective mechanism targeting the endocannabinoid system. By standardizing on the MAGL inhibition pathway, the patent reduces the diversity of drug mechanisms, thereby improving treatment reliability and reducing patient response variability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent segments the complex migraine treatment landscape by isolating a specific therapeutic target (MAGL enzyme) within the endocannabinoid system. This segmentation allows for a focused, standardized approach rather than treating the diverse nature of migraine with multiple different drug classes

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The approach effectively attenuates periorbital allodynia and facial sensitivity, providing a therapeutic strategy for preventing or treating headaches by targeting the endocannabinoid signaling system, which is critical in headache generation.

Implementation Method 1

The present invention relates to methods for enhancing 2-arachydonyl glycerol (2AG) tone... comprising administering to the mammal a pharmaceutical composition capable of enhancing 2AG tone... capable of inhibiting MAGL, ABHD6, or ABHD12 enzymes

Methodology Applied

Scientific EffectHydrolysis: Hydrolysis

Implementation Method 2

enhance DAGL activity, thereby modulating the endocannabinoid system

Methodology Applied

Scientific EffectEnzyme catalysis: Enzyme

Implementation Method 3

modulating the endocannabinoid system to alleviate headache symptoms... targeting the endocannabinoid signaling system

Methodology Applied

Scientific EffectEndocannabinoid signaling:

Data Source

PatentUS12599600B2Compositions and methods for preventing and treating headache through enhancing 2-arachydonyl glyerol activity

Publication Date: 2026.04.14 UNIV OF WASHINGTON

AI summary

This invention relates generally to compositions and methods for preventing, reducing the occurrence of or treating a headache in a subject in need thereof. In particular, the present invention relates to methods for enhancing 2-arachydonyl glycerol (2AG) tone and reducing prostaglandin activity in a subject for purposes of preventing, reducing the occurrence of or treating a headache (e.g., a migraine headache) in a subject.